Pharmafile Logo
Pharmafocus logo
Advanced Search

gilenya

Showing 15 posts of 35 posts found.

Novartis works in MS switch

June 11, 2013
Research and Development, Sales and Marketing MS, Novartis, gilenya

Novartis’ oral MS drug Gilenya has been found to help multiple sclerosis (MS) patients who switch to it after taking …

News
Tysabri image

Biogen and Elan file for Tysabri first line use in MS

January 18, 2013
Sales and Marketing Biogen IDEC, EMA, Elan, FDA, MS, Tsyabri, gilenya

Biogen Idec and Elan have applied to the FDA and EMA to expand Tysabri’s use in patients with relapsing forms …

News
Gilenya image

Novartis’ MS drug improves outcomes

October 15, 2012
Sales and Marketing MS, Novartis, gilenya

Novartis’ multiple sclerosis (MS) drug Gilenya has demonstrated what the manufacturer calls ‘significant’ benefits for patients if used early. Results …

News
Genzyme

Genzyme MS drug approved in US

September 13, 2012
Medical Communications Aubagio, Genzyme, Rebif, Sanofi, Tysabri, gilenya, multiple sclerosis

US regulators have given the green light for Genzyme’s Aubagio to treat patients with relapsing forms of multiple sclerosis (MS). …

News
Gilenya image

Gilenya to stay on US market – but with new safety warnings

May 15, 2012
Sales and Marketing EMA, FDA, Novartis, PML, gilenya

The FDA says that Novartis’ multiple sclerosis pill Gilenya should stay on the market, but has added new safety warnings …

News
Novartis image

Novartis to acquire Fougera for $1.5 billion

May 3, 2012
Sales and Marketing Fougera, Novartis, dermatology, generics, gilenya

Novartis will acquire the dermatology generics firm Fougera for $1.53 billion in cash.  Novartis’ generic unit Sandoz is conducting the …

News

Novartis Q1 earnings slide down

April 26, 2012
Sales and Marketing Novartis, Q1, Sandoz, generics, gilenya

Generic competition and problems at a US plant were among the reasons why Novartis’ sales and profit dipped in the …

News
Gilenya

New safety warnings recommended for Gilenya

April 20, 2012
Medical Communications, Sales and Marketing EMA, Novartis, gilenya

A safety review of Novartis’ MS treatment Gilenya has concluded the drug should stay on the market, but that patients …

News
Gilenya picture

NICE U-turn sees Gilenya MS pill recommended

March 16, 2012
Sales and Marketing MS, NICE, UK, fingolimod, gilenya

NICE has changed its mind on Novartis’ multiple sclerosis pill Gilenya, and is now recommending the drug in a subgroup …

News
Gilenya image

EMA to review safety of MS drug Gilenya

January 20, 2012
Research and Development, Sales and Marketing CHMP, EMA, Novartis, gilenya

The European Medicines Agency has begun a review into the safety of Novartis’ multiple sclerosis drug Gilenya. This follows concerns …

News
FDA picture

FDA to probe Gilenya patient death

December 21, 2011
Sales and Marketing FDA, Novartis, gilenya

The FDA is investigating Novartis’s new multiple sclerosis treatment Gilenya after a patient died within hours of taking the drug. …

News
Gilenya picture

Key product launches of 2011

December 19, 2011
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products

 Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …

Feature
Gilenya picture

Discount fails to sway NICE on Gilenya

December 1, 2011
Sales and Marketing NICE, Novartis, gilenya

NICE has once again rejected Novartis’ multiple sclerosis pill Gilenya despite the firm offering a patient access scheme. In its …

News

New MS drug shows promise for Abbott

August 10, 2011
Research and Development, Sales and Marketing Abbott, Avonex, Biogen, MS, gilenya

Biogen and Abbott’s multiple sclerosis drug daclizumab has performed well in a mid-stage trial, but two deaths marred the overall …

News
Gilenya

Gilenya rejected by NICE

August 5, 2011
Medical Communications, Sales and Marketing MS, NICE, Novartis, gilenya

NICE has not recommended Novartis’ multiple sclerosis drug Gilenya because of its cost and ‘uncertainties over its clinical effectiveness’. Gilenya …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024